As Executive Vice President of Diagnostics at Biosynth, Philip leads global business strategy, focusing on P&L, M&A, and product innovation. His extensive career includes roles as CEO at Aalto Bioreagents and VP at Trinity Biotech, where he consistently commercialized new diagnostic solutions. He holds a BSC from Technological University Dublin.
He has described himself as a "disease chaser," with a genuine interest in understanding emerging diseases, where and why they happen, and how they can be diagnosed and treated more quickly. This passion has driven his work from the beginning of his career.
Interesting fact: Early in his career, Philip helped develop diagnostic tests for numerous emerging diseases, including the Sin Nombre (SNV) strain of Hantavirus.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.